Literature DB >> 17562237

Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy.

Carlos Camps1, Rafael Sirera, Vega Iranzo, Miquel Tarón, Rafael Rosell.   

Abstract

Platinum compounds play a central role in cancer chemotherapy. Although treatment is limited by side effects, they continue to have widespread application. One of the main aims of clinical or translational research in cancer is the search for genetic factors that could foresee treatment outcomes, in biologic activity and toxic effects. This genetic analysis might allow selection of patients who will have the greatest benefit from chemotherapy. Furthermore, a better knowledge of the underlying molecular profile of the host and the tumor will facilitate screening for lung cancer susceptibility and tailoring of chemotherapy in individual patients, choosing those most likely to respond, adjusting doses more precisely in order to reduce less adverse effects, and establishing safety profiles based on individual genetic analyses. Herein, we discuss current knowledge regarding gene expression and polymorphisms of DNA repair enzymes in regard to cancer susceptibility and response to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17562237     DOI: 10.3816/CLC.2007.n.017

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  13 in total

1.  Evaluation of single nucleotide polymorphisms (SNPs) in the p53 binding protein 1 (TP53BP1) gene in breast cancer patients treated with breast-conserving surgery and whole-breast irradiation (BCS + RT).

Authors:  Bruce G Haffty; Sharad Goyal; Diptee Kulkarni; Camille Green; Alexi Vazquez; Devora Schiff; Meena S Moran; Qifeng Yang; Shridar Ganesan; Kim M Hirsfield
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-18       Impact factor: 7.038

Review 2.  Association of ERCC2/XPD polymorphisms and interaction with tobacco smoking in lung cancer susceptibility: a systemic review and meta-analysis.

Authors:  Zhen Feng; Yang Ni; Wei Dong; Hongchang Shen; Jiajun Du
Journal:  Mol Biol Rep       Date:  2011-05-26       Impact factor: 2.316

3.  A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer.

Authors:  Jian Cheng; Minwen Ha; Yadi Wang; Jing Sun; Junchen Chen; Yue Wang; Chunyan Tong
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-20       Impact factor: 4.553

Review 4.  Role of genotyping in non-small cell lung cancer treatment: current status.

Authors:  Laura Bonanno; Adolfo Favaretto; Massimo Rugge; Miquel Taron; Rafael Rosell
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

5.  ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.

Authors:  Chunxia Su; Songwen Zhou; Ling Zhang; Shengxiang Ren; Jianfang Xu; Jie Zhang; Meijun Lv; Jie Zhang; Caicun Zhou
Journal:  Med Oncol       Date:  2010-05-14       Impact factor: 3.064

6.  Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer.

Authors:  Ting Cheng; Xin Dai; Dan-Li Zhou; Yang Lv; Li-Yun Miao
Journal:  Med Oncol       Date:  2014-12-03       Impact factor: 3.064

7.  Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.

Authors:  Chunxia Su; Caicun Zhou; Songwen Zhou; Jianfang Xu
Journal:  Med Oncol       Date:  2010-08-17       Impact factor: 3.064

8.  Establishment of primary mouse lung adenocarcinoma cell culture.

Authors:  Shuli Luo; Mei Sun; Rui Jiang; Guan Wang; Xinyi Zhang
Journal:  Oncol Lett       Date:  2011-05-09       Impact factor: 2.967

9.  Individualized Chemotherapy in Advanced NSCLC Patients Based on mRNA Levels of BRCA1 and RRM1.

Authors:  Sheng-Xiang Ren; Ai-Wu Li; Song-Wen Zhou; Ling Zhang; Yong-Sheng Wang; Bing Li; Xiao-Xia Chen; Jie Zhang; Jian-Fang Xu; Cai-Cun Zhou
Journal:  Chin J Cancer Res       Date:  2012-09       Impact factor: 5.087

Review 10.  The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.

Authors:  Sophie Postel-Vinay; Elsa Vanhecke; Ken A Olaussen; Christopher J Lord; Alan Ashworth; Jean-Charles Soria
Journal:  Nat Rev Clin Oncol       Date:  2012-02-14       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.